Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 022308
Company: BAUSCH AND LOMB
Company: BAUSCH AND LOMB
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
BESIVANCE | BESIFLOXACIN HYDROCHLORIDE | EQ 0.6% BASE | SUSPENSION/DROPS;OPHTHALMIC | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
05/28/2009 | ORIG-1 | Approval | Type 1 - New Molecular Entity | STANDARD |
Label (PDF)
Letter (PDF) Review Summary Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022308lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022308s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022308s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022308s000_SumR.pdf |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
04/03/2018 | SUPPL-13 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022308s013lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/022308s013ltr.pdf | |
11/10/2015 | SUPPL-11 | Manufacturing (CMC) |
Label is not available on this site. |
||
04/07/2015 | SUPPL-10 | Manufacturing (CMC) |
Label is not available on this site. |
||
09/05/2014 | SUPPL-9 | Manufacturing (CMC) |
Label is not available on this site. |
||
04/30/2014 | SUPPL-8 | Manufacturing (CMC) |
Label is not available on this site. |
||
11/14/2013 | SUPPL-7 | Manufacturing (CMC) |
Label is not available on this site. |
||
05/10/2013 | SUPPL-6 | Manufacturing (CMC) |
Label is not available on this site. |
||
08/16/2013 | SUPPL-5 | Manufacturing (CMC) |
Label is not available on this site. |
||
09/18/2012 | SUPPL-3 | Efficacy-Labeling Change With Clinical Data |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022308s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022308Orig1s003ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
04/03/2018 | SUPPL-13 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022308s013lbl.pdf | |
09/18/2012 | SUPPL-3 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022308s003lbl.pdf | |
05/28/2009 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022308lbl.pdf |